Next Article in Journal
Effect of Dietary Bioactive Compounds on Mitochondrial and Metabolic Flexibility
Next Article in Special Issue
Prader-Willi Syndrome: The Disease that Opened up Epigenomic-Based Preemptive Medicine
Previous Article in Journal
Uric Acid for Cardiovascular Risk: Dr. Jekyll or Mr. Hide?
Previous Article in Special Issue
The Developmental Trajectory of Self-Injurious Behaviours in Individuals with Prader Willi Syndrome, Autism Spectrum Disorder and Intellectual Disability
Article Menu

Export Article

Open AccessReview
Diseases 2016, 4(1), 13; doi:10.3390/diseases4010013

Zebrafish Models of Prader-Willi Syndrome: Fast Track to Pharmacotherapeutics

Department of Oncology, Georgetown University Medical Center, 4000 Reservoir Road, N.W., Washington, DC 20057, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Danny Camfferman
Received: 31 December 2015 / Revised: 27 February 2016 / Accepted: 1 March 2016 / Published: 8 March 2016
(This article belongs to the Special Issue Prader-Willi Syndrome)
View Full-Text   |   Download PDF [1043 KB, uploaded 8 March 2016]   |  

Abstract

Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder characterized by an insatiable appetite, leading to chronic overeating and obesity. Additional features include short stature, intellectual disability, behavioral problems and incomplete sexual development. Although significant progress has been made in understanding the genetic basis of PWS, the mechanisms underlying the pathogenesis of the disorder remain poorly understood. Treatment for PWS consists mainly of palliative therapies; curative therapies are sorely needed. Zebrafish, Danio rerio, represent a promising way forward for elucidating physiological problems such as obesity and identifying new pharmacotherapeutic options for PWS. Over the last decade, an increased appreciation for the highly conserved biology among vertebrates and the ability to perform high-throughput drug screening has seen an explosion in the use of zebrafish for disease modeling and drug discovery. Here, we review recent advances in developing zebrafish models of human disease. Aspects of zebrafish genetics and physiology that are relevant to PWS will be discussed, and the advantages and disadvantages of zebrafish models will be contrasted with current animal models for this syndrome. Finally, we will present a paradigm for drug screening in zebrafish that is potentially the fastest route for identifying and delivering curative pharmacotherapies to PWS patients. View Full-Text
Keywords: neuroendocrine; oxytocin; zebrafish neuroendocrine; oxytocin; zebrafish
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Spikol, E.D.; Laverriere, C.E.; Robnett, M.; Carter, G.; Wolfe, E.; Glasgow, E. Zebrafish Models of Prader-Willi Syndrome: Fast Track to Pharmacotherapeutics. Diseases 2016, 4, 13.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top